Method for predicting cancer prognosis and composition thereof
A cost-effective method using six gene groups and RNA sequencing predicts cancer prognosis and chemotherapy suitability across all age ranges, enhancing accuracy and applicability beyond existing technologies.
Patent Information
- Application Number
- JP2021565712
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-03
- Filing Date
- 2020-04-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-04-28
AI Technical Summary
Existing cancer prognosis prediction methods, such as Oncotype Dx, are expensive and not applicable across all age groups, limiting their widespread use and effectiveness in determining the need for anticancer chemotherapy.
A method and device for predicting cancer prognosis using a set of six gene groups (ESR1, PGR, SCUBE2, CTSL2, MMP11, TFRC, CX3CR1, KIF14, RRM2, SHCBP1, SLC7A5, KPNA2, AURKA, CCNE2, CENPE, E2F8, KIF18A, KIF23, JMJD5, CACNA1D, GSTM1) with RNA sequencing and normalization, allowing for the calculation of a Decision Index (DI) to determine chemotherapy suitability across all age ranges.
The method provides accurate cancer prognosis and predicts chemotherapy response for all age groups, including women over 50, with improved accuracy compared to existing products like Oncotype Dx, and is cost-effective.
Smart Images

Figure 0007584151000001 
Figure 0007584151000002 
Figure 0007584151000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for predicting the prognosis of cancer and a composition thereof. More specifically, the present invention relates to a method for predicting the prognosis of cancer or a method for predicting whether or not anti-cancer chemotherapy will be effective, and a composition therefor. [Background technology]
[0002] Cancer is one of the most common causes of death worldwide. Approximately 10 million new cases occur each year, accounting for approximately 12% of all deaths and making it the third most common cause of death. Among various types of cancer, breast cancer in particular is the case of estrogen hormone receptor positive (ER+) breast cancer without axillary lymph node metastasis, which accounts for approximately half of the patients, with a 10-year recurrence rate of 15% after only 5 years of antihormone therapy, and the absolute value of the 10-year recurrence rate decreases to approximately 5% when anticancer chemotherapy is added (Fisher et al, Lancet. 10; 364 (9437): 858-68, PMID: 15351193). However, in 2004, the development of the Oncotype Dx test revealed that anticancer chemotherapy was necessary only in a portion of patients (see Paik et al, J Clin Oncol 24 (23): 3726-34, PMID: 16720680).
[0003] After the development of Oncotype Dx, many breast cancer prognostic prediction tests based on the analysis of transcriptional genes, such as Mammaprint, Endopredict, Breast Cancer Index, and Prosigna, have been developed and commercialized, but Oncotype Dx is the only test with proven clinical applicability for determining whether or not to use anticancer chemotherapy (US2015-0079591A1 and Paik et al, J Clin Oncol24(23):3726-34, PMID:16720680).
[0004] On the other hand, it has been confirmed that such Oncotype Dx is expensive and cannot be used to analyze all age ranges (see Wkilliams AD et al, Ann Surg Oncol. 2018Oct;25(10):2875-2883.doi:10.1245 / s10434-018-6600-9).
[0005] Therefore, the inventors of the present invention have discovered an apparatus and method for determining the prognosis of cancer and the suitability of anti-cancer chemotherapy as a method that can be used for analysis in all age groups, and have arrived at the present invention. Summary of the Invention [Problem to be solved by the invention]
[0006] An object of the present invention is to provide an apparatus which is inexpensive and capable of analyzing cancer prognosis and determining whether or not anti-cancer chemotherapy should be used in all age groups. [Means for solving the problem]
[0007] Various embodiments described in the present application will be described below with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and steps, are described for a complete understanding of the present invention. However, certain embodiments can be practiced without one or more of these specific details, or with other known methods and configurations. In other instances, known processes and manufacturing techniques are not described in specific detail so as not to unnecessarily obscure the present invention. References throughout this specification to "one embodiment" or "embodiments" mean that the particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the phrases "in one embodiment" or "embodiments" appearing in various locations throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
[0008] Unless otherwise defined within the present invention, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0009] As used herein, the term "polynucleotide", when used in the singular or plural form, generally refers to one polyribonucleotide or polydeoxyribonucleotide. This may be unmodified RNA or DNA, or modified RNA or DNA. Thus, for example, polynucleotides as defined herein include, but are not limited to, single-stranded and double-stranded DNA, DNA with single-stranded and double-stranded regions, single-stranded and double-stranded RNA, and RNA with single-stranded and double-stranded regions, hybrid molecules containing DNA and RNA that may be single-stranded, but more usually are double-stranded, or may contain single-stranded and double-stranded regions. Also, as used herein, the term "polynucleotide" refers to triple-stranded regions that contain RNA or DNA, or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. These regions may include all of one or more molecules, but more typically include only a portion of a molecule. One of the molecules in the double-helical region is an oligonucleotide. The term "polynucleotide" specifically includes cDNA. The term includes DNA (including cDNA) and RNA that contain one or more modified bases. Thus, DNA or RNA with backbones modified for stability or other reasons are "polynucleotides" as the term is intended herein. Also included within the term "polynucleotide" as defined herein are DNA or RNA that contain modified bases, such as unusual bases, e.g., inosine or tritiated bases. In general, the term "polynucleotide" includes all chemically, enzymatically, or metabolically modified forms of unmodified polynucleotides and the chemical forms of DNA and RNA characteristic of viruses and cells.
[0010] The term "oligonucleotide" refers to relatively short polynucleotides, such as, but not limited to, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids, and double-stranded DNA. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are synthesized by chemical methods using commercially available automated oligonucleotide synthesizers. In addition, oligonucleotides can be produced by a variety of other methods, such as in vitro recombinant DNA-mediated techniques, or by expression of DNA in cells and organisms.
[0011] The term "gene expression" refers to the conversion of DNA gene sequence information into transcribed RNA (the initial non-spliced RNA transcript or mature mRNA) or the coded protein product. Gene expression can be monitored by measuring the levels of one or the subsequent levels of the gene's total RNA or protein product.
[0012] With reference to RNA transcripts, the term "overexpression" is used to refer to the level of transcripts determined by measuring the levels of all transcripts measured in a sample or a particular reference set of mRNAs and normalizing to the level of the reference mRNA.
[0013] The term "gene amplification" refers to the process of forming multiple copies of a gene or gene fragment in a particular cell or cell line. The duplicated region (amplified DNA) is also called an "amplicon." Generally, the amount of mRNA produced, i.e., the level of gene expression, increases with the ratio of the number of copies made of each expressed gene.
[0014] As used herein, the term "prognosis" refers to the progression of a disease, such as migration and invasion of cancer into tissues, metastasis to other tissues, and death due to the disease, and whether or not the disease is cured. For the purposes of the present invention, prognosis refers to the prognosis of the disease or survival of a breast cancer patient. By using the method of the present invention, the prognosis of survival due to breast cancer can be easily determined, and the use of additional treatment methods can be easily determined. Ultimately, the survival rate after the onset of breast cancer can be improved.
[0015] In this specification, the term "prediction" refers to the act of predicting the course and outcome of a disease in advance for a patient with respect to a drug or set of drugs. More specifically, prognosis prediction is interpreted as any act of predicting the course of a disease after treatment by comprehensively considering the patient's condition, since the course of the disease after treatment varies depending on the patient's physiological or environmental condition.
[0016] As used herein, the term "beneficial response" refers to an improvement in any measure of patient status, such as overall survival, long-term survival, recurrence-free survival, and distant recurrence-free survival, as commonly used in the art. Recurrence-free survival (RFS) refers to the time (months) from surgery to the first local recurrence, regional recurrence, or distant recurrence. Distant recurrence-free survival (DRFS) or distant metastasis-free survival (DMFS)) refers to the time (months) from surgery to the first distant recurrence. Recurrence refers to RFS and / or DFRS. As used herein, the term "long-term" survival refers to survival for at least 3 years, or at least 5 years, or at least 8 years, or at least 10 years after surgery or other treatment.
[0017] As used herein, the term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or neoplastic, and all pre-cancerous and cancerous cells and tissues.
[0018] The terms "cancer" and "cancerous" refer to the physiological condition in mammals that is generally characterized by unregulated cell growth. Examples of cancer include breast cancer, glioma, thyroid cancer, lung cancer, liver cancer, pancreatic cancer, head and neck cancer, stomach cancer, colon cancer, urothelial cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, fallopian tube cancer, uterine cancer, blood cancer, bone cancer, skin cancer, brain cancer, vaginal cancer, endocrine cancer, parathyroid cancer, ureter cancer, urethral cancer, bronchial cancer, bladder cancer, bone marrow cancer, acute lymphocytic or lymphoblastic leukemia, acute or chronic lymphocytic leukemia, acute nonlymphocytic leukemia, brain tumor, cervical cancer, chronic myeloid leukemia, intestinal cancer, T-zone lymphoma, esophageal cancer, biliary bladder cancer, Ewing's sarcoma, and the like. sarcoma), tongue cancer, Hodgkin's lymphoma, Kaposi's sarcoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, neuroblastoma, breast cancer, cervical cancer, penile cancer, retinoblastoma, skin cancer, and uterine cancer.
[0019] The "pathology" of cancer includes all phenomena that compromise the health of a patient, including, but not limited to, abnormal or uncontrollable cell proliferation, metastasis, interference with the normal function of neighboring cells, release of abnormal levels of cytokines or other secretory products, suppressed or exacerbated inflammatory or immune responses, neoplasms, premalignant or malignant tumors, invasion of surrounding or distant tissues or organs, e.g., lymph nodes, etc.
[0020] In this specification, "Decision Index (DI)" refers to a score that can determine whether a subject's cancer prognosis is good or bad, and includes the concepts of prognostic factors and treatment predictors. Prognostic factors in breast cancer are different from treatment predictors. Prognostic factors are variables that are related to the natural death of breast cancer and affect the recurrence rate and outcome of patients with breast cancer. Clinical parameters associated with poor prognosis include, for example, lymph node involvement, tumor size increase, and high grade (malignant) tumors. Prognostic factors can be usefully used to classify patients into small groups with different basic recurrence risks. In contrast, treatment predictors are variables that are related to the possibility of each patient's beneficial response to treatment, such as anti-estrogen or chemotherapy, and are unrelated to prognosis.
[0021] In the present specification, nucleic acid sequence analysis including DNA or RNA may be next generation sequencing (NGS). Nucleic acid sequence analysis may be used interchangeably with base sequence analysis, sequence analysis, or sequencing. The NGS may be used interchangeably with massive parallel sequencing or second-generation sequencing. The NGS is a method for simultaneously analyzing the sequence of a large number of fragments of nucleic acid, and may be a chip-based or polymerase chain reaction (PCR)-based paired end format in which a full-length gene is divided into small pieces, and the small pieces are subjected to ultra-high speed sequence analysis based on hybridization. The NGS may be implemented using, for example, 454 platform (Roche), GS FLX Titanium, Illumina MiSeq, Illumina HiSeq, Illumina HiSeq 2500, Illumina Genome Analyzer, Solexa platform, SOLiD System (Applied Biosystems), Ion Proton (Life Technologies), Complete Genomics, Helicos Biosciences Heliscope, Pacific Biosciences Single Molecule Real Time (SMRT) TM ) technology, or a combination thereof. The nucleic acid sequence analysis may be a nucleic acid sequence analysis method for analyzing only a region of interest. The nucleic acid sequence analysis may include, for example, NGS-based targeted sequencing, targeted deep sequencing, or panel sequencing.
[0022] In this specification, "Next Generation Sequencing (NGS)" refers to a method of dividing a genome into numerous small pieces, decoding and combining the genetic information of each small piece, and then analyzing the entire base sequence. It has the advantage of being able to analyze the base sequence of a genome at high speed, and is also called high-throughput sequencing, massive parallel sequencing, or second-generation sequencing. Compared to NGS, Sanger sequencing can also read the entire human genome, but it can only target known genes, so the test is limited, and repeated experiments must be performed to see various genes. For example, compared to Sanger sequencing, which must be performed separately about 3 million times, next-generation sequencing is a greatly improved analysis method in terms of time and cost. Massively parallel base sequence analysis made possible by next-generation sequencing (NGS) technology is yet another method to approach the expression of RNA transcripts in tissue samples, and RNA-sequencing is a method that utilizes this. It is currently the most powerful analytical tool used to analyze transcripts, including differences in gene expression levels between different physiological conditions or changes that occur during development or disease progression. Specifically, RNA-sequencing can be used to study phenomena such as changes in gene expression, alternative splicing events, allele-specific gene expression and gene fusion events, de novo transcripts and chimeric transcripts including RNA editing.
[0023] In this specification, the term "probe" is a broad concept that comprehensively includes a probe that specifically attaches to a target gene to confirm and / or detect the target gene.
[0024] As used herein, "breast cancer" refers to a condition that is classified as a malignant pathological condition, for example, by biopsy. Clinical techniques for diagnosing breast cancer are well known in the medical arts. Those skilled in the art will appreciate that breast cancer refers to all malignancies of breast tissue, including, for example, carcinomas and sarcomas. In certain instances, the breast cancer is ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or mucinous carcinoma. Also, the breast cancer is infiltrating ductal carcinoma (IDC) or infiltrating lobular carcinoma (ILC). In most instances of the present invention, the intended subject is a human patient suspected or actually diagnosed with breast cancer.
[0025] "Early stage breast cancer" refers to stages 0 (in situ breast cancer), I (Tl, NO, MO), IIA (TO-1, Nl, MO or T2, NO, MO), and IIB (T2, Nl, MO or T3, NO, MO). Early stage breast cancer patients show little or no lymph node involvement. In this application, "lymph node involvement" or "lymph node status" refers to whether the cancer has spread to the lymph nodes. Breast cancer patients are classified as "node positive" or "node negative" based on this. Methods for differentiating breast cancer patients and staging the disease are well known and may include manual examination, biopsy, patient and / or family history examination, and imaging techniques such as mammography, magnetic resonance imaging (MRI), ultrasound (ultrasonography), computed tomography (CT), and positron emission tomography (PET).
[0026] Breast cancer is also managed by a variety of alternative strategies, which may include, for example, surgery, radiation therapy, hormonal therapy, chemotherapy, or some combination thereof. As known in the art, treatment decisions for individual breast cancer patients can be based on the number of involved lymph nodes, estrogen and progesterone receptor status, primary tumor size, and disease stage at diagnosis. Analysis of various clinical factors and clinical trials led the International Consensus Panel at the St. Gallen Conference (2001) to develop proposed recommendations and treatment guidelines for early stage breast cancer. See Goldhirsch et al. (200I) J. Clin. Oncol. 19:3817-3827.
[0027] As used herein, the term "subject" may refer to, but is not limited to, a patient who has developed or is suspected of developing breast cancer and who is expected to require or require appropriate treatment for breast cancer.
[0028] As used herein, the term "biological sample" refers to any sample in which genetic information of a patient can be confirmed, and may be, but is not limited to, blood, plasma, serum, etc., as long as the sample is of a type in which genes can be confirmed.
[0029] In this specification, the term "diagnostic device" refers to a device capable of diagnosing diseases outside the body based on substances produced in the human body, such as blood, saliva, and urine, and is not limited to a specific form as long as it includes, for example, a detection unit, a calculation unit, and an output unit, and is capable of analyzing genes from the substances.
[0030] According to one embodiment of the present invention, there is provided a method for providing information regarding cancer prognosis, comprising the steps of: (a) measuring and normalizing expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in a biological sample obtained from a subject; and (b) multiplying the normalized expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in step (a) by regression coefficient (weight) values, and adding these up to calculate a decision index (DI), thereby predicting the prognosis of cancer in the subject.
[0031] In the present invention, first, a step can be performed in which the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group are measured for a biological sample obtained from the subject.
[0032] In the present invention, the first group of genes may be any one or more selected from the group consisting of ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2).
[0033] In the present invention, the second group of genes may be any one or more selected from CTSL2 (Cathepsin V) and MMP11 (Matrix Metallopeptidase 11).
[0034] In the present invention, the third group of genes may be any one or more selected from TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1).
[0035] In the present invention, the fourth gene group may be any one or more selected from the group consisting of KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2).
[0036] In the present invention, the fifth group of genes may be any one or more selected from the group consisting of AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23).
[0037] In the present invention, the sixth gene group may be any one or more selected from the group consisting of JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1).
[0038] In the present invention, when the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group or the sixth gene group contains a plurality of genes, the step of measuring the expression level is carried out by measuring the expression level of each of the plurality of genes belonging to each gene group.
[0039] The expression level measurement according to the present invention is carried out by measuring the expression level of the gene from the mRNA extracted from a subject sample in the process of confirming the presence and expression level of the mRNA of the gene group. The analytical method for measuring the expression level includes, but is not limited to, RT-PCR, competitive RT-PCR, real-time RT-PCR, RNase protection assay (RPA), northern blotting, DNA microarray chip, etc., and may be any suitable method commonly used in the art.
[0040] The preparation for measuring the expression level of mRNA according to the present invention is preferably an antisense oligonucleotide, a primer or a probe, and a primer or a probe that specifically amplifies a specific region of the gene can be designed based on the base sequence of the gene group. The base sequences of the gene group according to the present invention are registered in GenBank and are known in the art, so that a person skilled in the art can design an antisense oligonucleotide, a primer or a probe that can specifically amplify a specific region of the gene based on the base sequence.
[0041] In the present invention, once the expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group are measured as described above, a step of normalizing the measured expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group can be carried out.
[0042] In the present invention, the normalization is performed by measuring the expression level of a reference gene, and then normalizing each of the expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group to the measured expression level of the reference gene.
[0043] In the present invention, the expression level of differentially expressed genes can be calculated by using the number of reads mapped by RNA sequencing to confirm the expression level of each gene or transcript of each sample. However, since defining the expression level based on the number of mapped reads involves errors for each sample and is difficult to call an objective value, a normalization process was performed as a method for deriving an objective value.
[0044] Generally, when analyzing RNA sequencing expression, there are various methods mainly used in the industry to calculate and normalize FPKM (Fragments Per Kilobase of transcripts per Million mapped reads), RPKM (Reads Per Kilobase of transcript per Million mapped reads), TPM (Transcripts Per Million), and TMM (Trimmed Mean of M-value) values.
[0045] Among the previously used normalization methods, the Trimmed Mean of M-value (TMM) method used in the R package edgeR (Robinson et al. Bioinformatics 2010) is known to be the safest (Dillies et al. Briefings in bioinformatics 2013). In the present invention, a pipeline can be designed and used to automatically extract normalized gene expression information from targeted RNA sequencing data produced using the edgeR package. The sequencing data generated using NGS technology is mapped to a reference gene using commonly used alignment software (RNA-STAR) (Dobin et al. Bioinformatics 2013). The number of sequences from each gene is counted through the mapping results, and a direct estimate of the gene expression level is extracted. The normalization pipeline developed inputs the data that has been mapped and processed into a BAM file format, and the mapped data is calculated into normalized expression values that can be compared between samples using a series of software packages built into the pipeline (htseq-count (Anders et al. Bioinformatics 2014), edgeR (Robinson et al. Bioinformatics 2010)).
[0046] More specifically, the "normalization process" of the present invention removes low-quality reads and artificially generated reads from among the reads generated using NGS technology, maps them to the sequence of a human reference gene using STAR aligner software, and extracts only the exon region (conserved exon) that has been mapped and stored in the BAM file format to further improve stability. After the process, the expression level of each gene is quantified using htseq-count. The quantified expression level is obtained using the Trimmed Mean of M-value (TMM) method used in the R package edgeR, which is one of the previously used normalization methods. In particular, normalization is performed by adding the normalized patient group, and this modified TMM method has higher stability than other existing normalization methods. Through this series of processes, a normalized expression value that allows comparison between samples is calculated. However, the normalization method is not limited to this as long as it corresponds to a normalization method commonly used in the art.
[0047] In the present invention, the "reference gene" refers to any transcript that maintains approximately the same level regardless of cell or tissue type or the presence of a perturbing agent (i.e., for example, a perturbation source). In the present invention, the reference gene can be useful as an internal control for normalizing gene expression data.
[0048] In the present invention, the type of the reference gene is not particularly limited, and examples thereof include ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCNA2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, C RIM1, CYBRD1, DBF4, DDX39, DLGAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERCC6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH , GINS1, GRB7, GTSE1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20A, KIF2C, KIF4A, KIFC1, LMNB1, LMNB2, LRIG1, LRRC48, LRRC59, MAD2L 1, MARCH8, MCM10, MCM2, MCM6, MELK, MKI67, MLF1IP, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYT1, PLK1, PLK4, PRC1, PTTG1, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLP0, SETBP1, SF3B3, SHMT2, SLC25A12, SPAG5, SPC25, SQLE, STARD13, STIL, STMN1, SYNC, TACC3, TK1, TOP2A, TPX2, TRIP13, TROAP, TTK, UBE2C, UBE2S, ZWINT, C10orf76, C12orf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNPK, HNRNPL, HNRNPR, J MJD5, KHDRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, PKNOX1, PPHLN1, RRN3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11,It may be any one or more selected from the group consisting of WDR33, and ZNF143.
[0049] In the present invention, when the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group or the sixth gene group contains multiple genes, the normalization is performed on each of the multiple genes belonging to each gene group.
[0050] In the present invention, after normalizing the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group as described above, a step can be performed in which the normalized expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group are multiplied by a regression coefficient (weight) value and then summed up to calculate a decision index (DI).
[0051] In the present invention, the regression coefficient value by which the normalized expression levels of the first group of genes are multiplied may be a rational number ranging from −2.36 to −0.34.
[0052] In the present invention, the regression coefficient value by which the normalized expression levels of the second group of genes are multiplied may be a rational number ranging from 0.17 to 0.42.
[0053] In the present invention, the regression coefficient value by which the normalized expression levels of the third gene group are multiplied may be a rational number ranging from −0.06 to 0.22.
[0054] In the present invention, the regression coefficient value by which the normalized expression levels of the fourth gene group are multiplied may be a rational number ranging from 0.01 to 0.73.
[0055] In the present invention, the regression coefficient value by which the normalized expression levels of the fifth gene group are multiplied may be a rational number between 0.08 and 0.65.
[0056] In the present invention, the regression coefficient value by which the normalized expression levels of the sixth gene group are multiplied may be a rational number ranging from −0.58 to −0.02.
[0057] In the present invention, when the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, or the sixth gene group includes a plurality of genes, the normalized expression levels of the plurality of genes belonging to each gene group can be multiplied by a regression coefficient value. In this case, even if the plurality of genes belong to the same gene group, the regression coefficient values by which the normalized expression levels of each of the genes are multiplied can be the same or different.
[0058] In the present invention, the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group normalized as described above can be multiplied by the regression coefficient value and then summed to obtain a decision index (DI); however, preferably, a correction coefficient value can be additionally added.
[0059] In the present invention, the correction coefficient value may be a rational number between 35.09 and 47.07.
[0060] Therefore, in the present invention, the decision index (DI) may be expressed as follows in Equation 1:
[0061] [Formula 1] DI=aX(q)+bY(r)+cZ(s)+dK(t)+eL(u)+fM(v)
[0062] In the above formula 1, q, r, s, t, u and v are each independently an integer of 1 or more, preferably an integer of 1 to 6, and more preferably, the q is an integer of 1 to 3, the r is an integer of 1 to 2, the s is an integer of 1 to 2, the t is an integer of 1 to 5, the u is an integer of 1 to 6, and the v is an integer of 1 to 3.
[0063] The a is a regression coefficient value by which the normalized expression levels of the first group of genes are multiplied, and may be a rational number ranging from −2.36 to −0.34.
[0064] The b is a regression coefficient value by which the normalized expression levels of the second group of genes are multiplied, and may be a rational number between 0.17 and 0.42.
[0065] The c is a regression coefficient value by which the normalized expression levels of the third group of genes are multiplied, and may be a rational number ranging from −0.06 to 0.22.
[0066] The d is a regression coefficient value by which the normalized expression levels of the fourth gene group are multiplied, and may be a rational number between 0.01 and 0.73.
[0067] The e is a regression coefficient value by which the normalized expression levels of the fifth gene group are multiplied, and may be a rational number between 0.08 and 0.65.
[0068] The f is a regression coefficient value by which the normalized expression levels of the sixth gene group are multiplied, and may be a rational number between −0.58 and −0.02.
[0069] The X(q) may be the sum of normalized expression levels of q genes belonging to the first gene group. However, when the q is 1, the X(q) may be the value of the normalized expression level of any one of the genes belonging to the first gene group. Furthermore, the aX(q) may be the sum of values obtained by multiplying each of the normalized expression levels of the q genes belonging to the first gene group by a, and when the q is an integer of 2 or more, the a values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0070] The Y(r) may be the sum of normalized expression levels of r genes belonging to the second gene group. However, when the r is 1, the Y(r) may be the value of the normalized expression level of any one of the genes belonging to the second gene group. The bY(r) may be the sum of values obtained by multiplying each of the normalized expression levels of the r genes belonging to the second gene group by b, and when the r is an integer of 2 or more, the b values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0071] The Z(s) may be the sum of normalized expression levels of s genes belonging to the third gene group. However, when the s is 1, the Z(s) may be the value of the normalized expression level of any one of the genes belonging to the third gene group. The cZ(s) may be the sum of values obtained by multiplying each of the normalized expression levels of the s genes belonging to the third gene group by c, and when the s is an integer of 2 or more, the c values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0072] The K(t) may be the sum of normalized expression levels of t genes belonging to the fourth gene group. However, when the t is 1, the K(t) may be the value of the normalized expression level of any one of the genes belonging to the fourth gene group. The dK(t) may be the sum of values obtained by multiplying each of the normalized expression levels of the t genes belonging to the fourth gene group by d, and when the t is an integer of 2 or more, the d values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0073] The L(u) may be the sum of normalized expression levels of u genes belonging to the fifth gene group. However, when the u is 1, the L(u) may be the value of the normalized expression level of any one of the genes belonging to the fifth gene group. The eL(u) may be the sum of values obtained by multiplying each of the normalized expression levels of the u genes belonging to the fifth gene group by e, and when the u is an integer of 2 or more, the e values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0074] The M(v) may be the sum of normalized expression levels of v genes belonging to the sixth gene group. However, when the v is 1, the M(v) may be the value of the normalized expression level of any one of the genes belonging to the sixth gene group. The fM(v) may be the sum of values obtained by multiplying the normalized expression levels of the v genes belonging to the sixth gene group by f, and when the v is an integer of 2 or more, the f values by which the normalized expression levels of the respective genes are multiplied may be the same or different.
[0075] In the present invention, more specifically, the aX(q) may be represented by the following formula 2.
[0076] [Formula 2] aX(q)=a1*X1+…+a q *X q
[0077] In the above formula 2, q is an integer of 1 or more, preferably an integer of 1 to 3; a1~a q are each independently rational numbers between -2.36 and -0.34, X1~X q may each independently be a normalized expression level of any gene belonging to the first group of genes.
[0078] In the present invention, the bY(r) may be represented by the following formula 3.
[0079] [Formula 3] bY(r)=b1*Y1+…+b q *Y q
[0080] In the above formula 3, r is an integer of 1 or more, preferably an integer of 1 to 2; b1~b q are each independently rational numbers between 0.17 and 0.42, Y1~Y q may each independently be a normalized expression level of any gene belonging to the second group of genes.
[0081] In the present invention, the cZ(s) may be expressed by the following formula 4.
[0082] [Formula 4] cZ(s)=c1*Z1+…+c q *Z q
[0083] In the above formula 4, s is an integer of 1 or more, preferably an integer of 1 to 2; c1~c q are each independently a rational number between -0.06 and 0.22, Z1~Z q may each independently be a normalized expression level of any gene belonging to the third group of genes.
[0084] In the present invention, the dK(t) may be expressed by the following formula 5.
[0085] [Formula 5] dK(t)=d1*K1+…+d q *K q
[0086] In the above formula 5, t is an integer of 1 or more, preferably an integer of 1 to 5; d1~d q are each independently a rational number between 0.01 and 0.73, K1~K q may each independently be a normalized expression level of any gene belonging to the fourth group of genes.
[0087] In the present invention, the eL(u) may be expressed by the following formula 6.
[0088] [Formula 6] eL(u)=e1*L1+…+e q *L q
[0089] In the above formula 6, u is an integer of 1 or more, preferably an integer of 1 to 6; e1~e q are each independently rational numbers between 0.08 and 0.65, L1~L q may each independently be a normalized expression level of any gene belonging to the fifth group of genes.
[0090] In the present invention, the fM(v) may be expressed by the following formula 7.
[0091] [Formula 7] fM(v)=f1*M1+…+f q *M q
[0092] In the above formula 7, v is an integer of 1 or more, preferably an integer of 1 to 3; f1~f q are each independently rational numbers between -0.58 and -0.02, M1~M q may each independently be a normalized expression level of any gene belonging to the sixth group of genes.
[0093] In the present invention, the method may further include a step of predicting that the prognosis of cancer is poor if the calculated decision index (DI) value exceeds 20.
[0094] In the present invention, the cancer is breast cancer, glioma, thyroid cancer, lung cancer, liver cancer, pancreatic cancer, head and neck cancer, gastric cancer, colon cancer, urothelial cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, fallopian tube cancer, uterine cancer, blood cancer, bone cancer, skin cancer, brain cancer, vaginal cancer, endocrine cancer, parathyroid cancer, ureter cancer, urethral cancer, bronchial cancer, bladder cancer, bone marrow cancer, acute lymphocytic or lymphoblastic leukemia, acute or chronic lymphocytic leukemia, acute nonlymphocytic leukemia, brain tumor, cervical cancer, chronic myeloid leukemia, intestinal cancer, T-zone lymphoma, esophageal cancer, biliary bladder cancer, Ewing's sarcoma, sarcoma), tongue cancer, Hodgkin's lymphoma, Kaposi's sarcoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, neuroblastoma, breast cancer, cervical cancer, penile cancer, retinoblastoma, skin cancer, and uterine cancer.
[0095] The method for providing information regarding cancer prognosis of the present invention can be used not only to predict the prognosis of cancer in a subject, but also to predict whether or not a subject can undergo chemical anticancer therapy, the therapeutic response to chemical anticancer therapy, or the prognosis after chemical anticancer therapy.
[0096] According to another embodiment of the present invention, there is provided a composition for predicting cancer prognosis, comprising a preparation for measuring the expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group and a sixth gene group in a biological sample obtained from a subject.
[0097] In the present invention, the first group of genes may be any one or more selected from the group consisting of ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2).
[0098] In the present invention, the second group of genes may be any one or more selected from CTSL2 (Cathepsin V) and MMP11 (Matrix Metallopeptidase 11).
[0099] In the present invention, the third group of genes may be any one or more selected from TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1).
[0100] In the present invention, the fourth gene group may be any one or more selected from the group consisting of KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2).
[0101] In the present invention, the fifth group of genes may be any one or more selected from the group consisting of AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23).
[0102] In the present invention, the sixth gene group may be any one or more selected from the group consisting of JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1).
[0103] In the present invention, the preparation for measuring the expression level of the gene may be, but is not limited to, an antisense oligonucleotide, primer or probe capable of specifically binding to each of the genes of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group.
[0104] The composition for predicting cancer prognosis of the present invention may further comprise a preparation for measuring the expression level of a reference gene for normalizing the expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group.
[0105] In the present invention, the type of the reference gene is not particularly limited, and examples thereof include ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCNA2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, C RIM1, CYBRD1, DBF4, DDX39, DLGAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERCC6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH , GINS1, GRB7, GTSE1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20A, KIF2C, KIF4A, KIFC1, LMNB1, LMNB2, LRIG1, LRRC48, LRRC59, MAD2L 1, MARCH8, MCM10, MCM2, MCM6, MELK, MKI67, MLF1IP, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYT1, PLK1, PLK4, PRC1, PTTG1, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLP0, SETBP1, SF3B3, SHMT2, SLC25A12, SPAG5, SPC25, SQLE, STARD13, STIL, STMN1, SYNC, TACC3, TK1, TOP2A, TPX2, TRIP13, TROAP, TTK, UBE2C, UBE2S, ZWINT, C10orf76, C12orf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNPK, HNRNPL, HNRNPR, J MJD5, KHDRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, PKNOX1, PPHLN1, RRN3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11,It may be any one or more selected from the group consisting of WDR33, and ZNF143.
[0106] In the present invention, the cancer is breast cancer, glioma, thyroid cancer, lung cancer, liver cancer, pancreatic cancer, head and neck cancer, gastric cancer, colon cancer, urothelial cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, fallopian tube cancer, uterine cancer, blood cancer, bone cancer, skin cancer, brain cancer, vaginal cancer, endocrine cancer, parathyroid cancer, ureter cancer, urethral cancer, bronchial cancer, bladder cancer, bone marrow cancer, acute lymphocytic or lymphoblastic leukemia, acute or chronic lymphocytic leukemia, acute nonlymphocytic leukemia, brain tumor, cervical cancer, chronic myeloid leukemia, intestinal cancer, T-zone lymphoma, esophageal cancer, biliary bladder cancer, Ewing's sarcoma, sarcoma), tongue cancer, Hodgkin's lymphoma, Kaposi's sarcoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, neuroblastoma, breast cancer, cervical cancer, penile cancer, retinoblastoma, skin cancer, and uterine cancer.
[0107] The composition for predicting cancer prognosis of the present invention can not only predict the prognosis of cancer in a subject, but can also be used to predict whether or not a subject can undergo chemical anticancer therapy, the therapeutic response to chemical anticancer therapy, or the prognosis after chemical anticancer therapy.
[0108] According to yet another embodiment of the present invention, there is provided a cancer prognosis diagnostic device comprising: (a) a detection unit that measures and normalizes expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group, and a sixth gene group in a biological sample obtained from a subject; (b) a calculation unit that multiplies each expression level of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group normalized by the detection unit by a regression coefficient (weight) value and calculates a decision index (DI) obtained by adding up the expression levels; and (c) an output unit that predicts and outputs the prognosis of cancer in the subject using the decision index obtained by the calculation unit.
[0109] In the present invention, the detection unit can measure the expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group from the biological sample obtained from the subject.
[0110] In the present invention, the first group of genes may be any one or more selected from the group consisting of ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2).
[0111] In the present invention, the second group of genes may be any one or more selected from CTSL2 (Cathepsin V) and MMP11 (Matrix Metallopeptidase 11).
[0112] In the present invention, the third group of genes may be any one or more selected from TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1).
[0113] In the present invention, the fourth gene group may be any one or more selected from the group consisting of KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2).
[0114] In the present invention, the fifth group of genes may be any one or more selected from the group consisting of AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23).
[0115] In the present invention, the sixth gene group may be any one or more selected from the group consisting of JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1).
[0116] In the present invention, the detection unit can normalize the measured expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group to the expression level of a reference gene.
[0117] In the present invention, the type of the reference gene is not particularly limited, and examples thereof include ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCNA2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, C RIM1, CYBRD1, DBF4, DDX39, DLGAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERCC6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH , GINS1, GRB7, GTSE1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20A, KIF2C, KIF4A, KIFC1, LMNB1, LMNB2, LRIG1, LRRC48, LRRC59, MAD2L 1, MARCH8, MCM10, MCM2, MCM6, MELK, MKI67, MLF1IP, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYT1, PLK1, PLK4, PRC1, PTTG1, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLP0, SETBP1, SF3B3, SHMT2, SLC25A12, SPAG5, SPC25, SQLE, STARD13, STIL, STMN1, SYNC, TACC3, TK1, TOP2A, TPX2, TRIP13, TROAP, TTK, UBE2C, UBE2S, ZWINT, C10orf76, C12orf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNPK, HNRNPL, HNRNPR, J MJD5, KHDRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, PKNOX1, PPHLN1, RRN3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11,The gene may be any one or more selected from the group consisting of WDR33, ZNF143, or ZNF143.
[0118] In the detection section of the present invention, the preparation used to measure the expression level of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, the sixth gene group or the reference gene, as well as the measurement method and normalization method thereof, overlap with those described in the method of providing information regarding cancer prognosis of the present invention, and therefore detailed description thereof will be omitted below.
[0119] In the present invention, after normalizing the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group in the detection unit, the calculation unit multiplies the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group normalized in the detection unit by a regression coefficient (weight) value, and adds these up to calculate a decision index (DI).
[0120] In the present invention, the regression coefficient value by which the normalized expression levels of the first group of genes are multiplied may be a rational number ranging from −2.36 to −0.34.
[0121] In the present invention, the regression coefficient value by which the normalized expression levels of the second group of genes are multiplied may be a rational number ranging from 0.17 to 0.42.
[0122] In the present invention, the regression coefficient value by which the normalized expression levels of the third gene group are multiplied may be a rational number ranging from −0.06 to 0.22.
[0123] In the present invention, the regression coefficient value by which the normalized expression levels of the fourth gene group are multiplied may be a rational number ranging from 0.01 to 0.73.
[0124] In the present invention, the regression coefficient value by which the normalized expression levels of the fifth gene group are multiplied may be a rational number between 0.08 and 0.65.
[0125] In the present invention, the regression coefficient value by which the normalized expression levels of the sixth gene group are multiplied may be a rational number ranging from −0.58 to −0.02.
[0126] In the present invention, when the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, or the sixth gene group includes a plurality of genes, the normalized expression levels of the plurality of genes belonging to each gene group can be multiplied by a regression coefficient value. In this case, even if the plurality of genes belong to the same gene group, the regression coefficient values by which the normalized expression levels of each of the genes are multiplied can be the same or different.
[0127] In the present invention, the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group normalized as described above can be multiplied by the regression coefficient value and then summed to obtain a decision index (DI); however, preferably, a correction coefficient value can be additionally added.
[0128] In the present invention, the correction coefficient value may be a rational number between 35.09 and 47.07.
[0129] In the present invention, the Decision Index (DI) may be expressed as follows:
[0130] [Formula 1] DI=aX(q)+bY(r)+cZ(s)+dK(t)+eL(u)+fM(v)
[0131] In the above formula 1, q, r, s, t, u and v are each independently an integer of 1 or more, preferably an integer of 1 to 6, and more preferably, the q is an integer of 1 to 3, the r is an integer of 1 to 2, the s is an integer of 1 to 2, the t is an integer of 1 to 5, the u is an integer of 1 to 6, and the v is an integer of 1 to 3.
[0132] The a is a regression coefficient value by which the normalized expression levels of the first group of genes are multiplied, and may be a rational number ranging from −2.36 to −0.34.
[0133] The b is a regression coefficient value by which the normalized expression levels of the second group of genes are multiplied, and may be a rational number between 0.17 and 0.42.
[0134] The c is a regression coefficient value by which the normalized expression levels of the third group of genes are multiplied, and may be a rational number ranging from −0.06 to 0.22.
[0135] The d is a regression coefficient value by which the normalized expression levels of the fourth gene group are multiplied, and may be a rational number between 0.01 and 0.73.
[0136] The e is a regression coefficient value by which the normalized expression levels of the fifth gene group are multiplied, and may be a rational number between 0.08 and 0.65.
[0137] The f is a regression coefficient value by which the normalized expression levels of the sixth gene group are multiplied, and may be a rational number between −0.58 and −0.02.
[0138] The X(q) may be the sum of normalized expression levels of q genes belonging to the first gene group. However, when the q is 1, the X(q) may be the value of the normalized expression level of any one of the genes belonging to the first gene group. Furthermore, the aX(q) may be the sum of values obtained by multiplying each of the normalized expression levels of the q genes belonging to the first gene group by a, and when the q is an integer of 2 or more, the a values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0139] The Y(r) may be the sum of normalized expression levels of r genes belonging to the second gene group. However, when the r is 1, the Y(r) may be the value of the normalized expression level of any one of the genes belonging to the second gene group. The bY(r) may be the sum of values obtained by multiplying each of the normalized expression levels of the r genes belonging to the second gene group by b, and when the r is an integer of 2 or more, the b values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0140] The Z(s) may be the sum of normalized expression levels of s genes belonging to the third gene group. However, when the s is 1, the Z(s) may be the value of the normalized expression level of any one of the genes belonging to the third gene group. The cZ(s) may be the sum of values obtained by multiplying each of the normalized expression levels of the s genes belonging to the third gene group by c, and when the s is an integer of 2 or more, the c values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0141] The K(t) may be the sum of normalized expression levels of t genes belonging to the fourth gene group. However, when the t is 1, the K(t) may be the value of the normalized expression level of any one of the genes belonging to the fourth gene group. The dK(t) may be the sum of values obtained by multiplying each of the normalized expression levels of the t genes belonging to the fourth gene group by d, and when the t is an integer of 2 or more, the d values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0142] The L(u) may be the sum of normalized expression levels of u genes belonging to the fifth gene group. However, when the u is 1, the L(u) may be the value of the normalized expression level of any one of the genes belonging to the fifth gene group. The eL(u) may be the sum of values obtained by multiplying each of the normalized expression levels of the u genes belonging to the fifth gene group by e, and when the u is an integer of 2 or more, the e values by which the normalized expression levels of each gene are multiplied may be the same or different.
[0143] The M(v) may be the sum of normalized expression levels of v genes belonging to the sixth gene group. However, when the v is 1, the M(v) may be the value of the normalized expression level of any one of the genes belonging to the sixth gene group. The fM(v) may be the sum of values obtained by multiplying the normalized expression levels of the v genes belonging to the sixth gene group by f, and when the v is an integer of 2 or more, the f values by which the normalized expression levels of the respective genes are multiplied may be the same or different.
[0144] In the present invention, more specifically, the aX(q) may be represented by the following formula 2.
[0145] [Formula 2] aX(q)=a1*X1+…+a q *X q
[0146] In the above formula 2, q is an integer of 1 or more, preferably an integer of 1 to 3; a1~a q are each independently rational numbers between -2.36 and -0.34, X1~X q may each independently represent a normalized expression level of any gene belonging to the first gene group. In the present invention, the bY(r) may be represented by the following formula 3.
[0147] [Formula 3] bY(r)=b1*Y1+…+b q *Y q
[0148] In the above formula 3, r is an integer of 1 or more, preferably an integer of 1 to 2; b1~b q are each independently rational numbers between 0.17 and 0.42, Y1~Y q may each independently be a normalized expression level of any gene belonging to the second group of genes.
[0149] In the present invention, the cZ(s) may be expressed by the following formula 4.
[0150] [Formula 4] cZ(s)=c1*Z1+…+c q *Z q
[0151] In the above formula 4, s is an integer of 1 or more, preferably an integer of 1 to 2; c1~c q are each independently a rational number between -0.06 and 0.22, Z1~Z q may each independently be a normalized expression level of any gene belonging to the third group of genes.
[0152] In the present invention, the dK(t) may be expressed by the following formula 5.
[0153] [Formula 5] dK(t)=d1*K1+…+d q *K q
[0154] In the above formula 5, t is an integer of 1 or more, preferably an integer of 1 to 5; d1~d q are each independently a rational number between 0.01 and 0.73, K1~K q may each independently be a normalized expression level of any gene belonging to the fourth group of genes.
[0155] In the present invention, the eL(u) may be expressed by the following formula 6.
[0156] [Formula 6] eL(u)=e1*L1+…+e q *L q
[0157] In the above formula 6, u is an integer of 1 or more, preferably an integer of 1 to 6; e1~e q are each independently rational numbers between 0.08 and 0.65, L1~L q may each independently be a normalized expression level of any gene belonging to the fifth group of genes.
[0158] In the present invention, the fM(v) may be expressed by the following formula 7.
[0159] [Formula 7] fM(v)=f1*M1+…+f q *M q
[0160] In the above formula 7, v is an integer of 1 or more, preferably an integer of 1 to 3; f1~f q are each independently rational numbers between -0.58 and -0.02, M1~M q may each independently be a normalized expression level of any gene belonging to the sixth group of genes.
[0161] The output unit of the present invention can predict and output the prognosis of cancer in the subject based on the determination index (DI) obtained by the calculation unit, and can predict and output a poor prognosis when the determination index (DI) value exceeds 20.
[0162] In the present invention, the cancer is breast cancer, glioma, thyroid cancer, lung cancer, liver cancer, pancreatic cancer, head and neck cancer, gastric cancer, colon cancer, urothelial cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, fallopian tube cancer, uterine cancer, blood cancer, bone cancer, skin cancer, brain cancer, vaginal cancer, endocrine cancer, parathyroid cancer, ureter cancer, urethral cancer, bronchial cancer, bladder cancer, bone marrow cancer, acute lymphocytic or lymphoblastic leukemia, acute or chronic lymphocytic leukemia, acute nonlymphocytic leukemia, brain tumor, cervical cancer, chronic myeloid leukemia, intestinal cancer, T-zone lymphoma, esophageal cancer, biliary bladder cancer, Ewing's sarcoma, sarcoma), tongue cancer, Hodgkin's lymphoma, Kaposi's sarcoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, neuroblastoma, breast cancer, cervical cancer, penile cancer, retinoblastoma, skin cancer, and uterine cancer.
[0163] The cancer prognosis diagnostic device of the present invention can not only predict the prognosis of cancer in a subject, but can also be used to predict whether or not a subject should undergo chemical anti-cancer therapy, the therapeutic response to chemical anti-cancer therapy, or the prognosis after chemical anti-cancer therapy. Effect of the Invention
[0164] According to the present invention, it is possible to predict the prognosis of cancer for all age groups from 20s to 80s, and in particular, it is possible to predict the prognosis of cancer for all women aged 50 years or older or younger than 50. Also, according to the present invention, it is possible to predict whether a cancer patient is likely to have a beneficial response to chemotherapy. [Brief description of the drawings]
[0165] [Figure 1] 1A and 1B are graphs showing the results of predicting the prognosis of breast cancer using the method for providing information on cancer prognosis according to the present invention, compared with a conventional product. [Diagram 2] 1 is a graph confirming risk ratios when carried out using the method for providing information regarding cancer prognosis according to the present invention. [Figure 3A] 1 is a graph comparing the cancer prognosis information providing method according to the present invention with cases in which the patient's age is around 50 years old. [Figure 3B] 1 is a graph comparing the cancer prognosis information providing method according to the present invention with cases in which the patient's age is around 50 years old. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0166] According to one embodiment of the present invention, the present invention relates to a method for providing information regarding cancer prognosis, comprising the steps of: (a) measuring and normalizing expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group, and a sixth gene group in a biological sample obtained from a subject; and (b) multiplying the normalized expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in step (a) by regression coefficient (weight) values, and adding these up to calculate a decision index (DI), thereby predicting the prognosis of cancer in the subject.
[0167] According to another embodiment of the present invention, the present invention relates to a composition for predicting cancer prognosis, comprising a preparation for measuring the expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group and a sixth gene group in a biological sample obtained from a subject.
[0168] According to yet another embodiment of the present invention, the present invention relates to a cancer prognosis diagnostic device, comprising: (a) a detection unit that measures and normalizes expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group, and a sixth gene group in a biological sample obtained from a subject; (b) a calculation unit that multiplies each expression level of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group normalized by the detection unit by a regression coefficient (weight) value and calculates a decision index (DI) obtained by adding up the expression levels; and (c) an output unit that predicts and outputs the prognosis of cancer in the subject using the decision index obtained by the calculation unit.
[0169] In the present invention, the first group of genes may be any one or more selected from the group consisting of ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2).
[0170] In the present invention, the second group of genes may be any one or more selected from CTSL2 (Cathepsin V) and MMP11 (Matrix Metallopeptidase 11).
[0171] In the present invention, the third group of genes may be any one or more selected from TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1).
[0172] In the present invention, the fourth gene group may be any one or more selected from the group consisting of KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2).
[0173] In the present invention, the fifth group of genes may be any one or more selected from the group consisting of AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23).
[0174] In the present invention, the sixth gene group may be any one or more selected from the group consisting of JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1). EXAMPLES
[0175] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention in more detail, and that the scope of the present invention is not limited by these examples according to the gist of the present invention.
[0176] Working Example
[0177] Selection of breast cancer patients and preparation of test tissue
[0178] Representative formalin-fixed paraffin-embedded (FFPE) blocks were selected from surgical tissues of stage 1-2 breast cancer patients who were hormone receptor positive and lymph node metastasis negative, and RNA was extracted from them.
[0179] Targeted RNA-Sequencing
[0180] Once a certain level of RNA quality was obtained, a cDNA library was made from this. A 179-gene panel probe was used to detect only specific genes. All 179 genes were sequenced using a next-generation sequencing (NGS) device and aligned to the human genome. They were mapped to the public human genome reference using the alignment algorithm called STAR. The expression level of each gene was measured from the information of the aligned analysis sequences.
[0181] Normalization of target RNA-sequencing expression data
[0182] Normalization was performed using the patients and patient genes used in modeling. Normalization was performed using 343 patients and 179 genes. Only 21 genes were used to calculate the recurrence score, and all genes were used in normalization.
[0183] The present invention provides genes and gene sets that are useful for predicting the response of cancer, e.g., breast cancer, patients to chemotherapy. The present invention also provides a clinically effective test for predicting the response of breast cancer patients to chemotherapy, utilizing multiple gene RNA analysis.
[0184] The present inventors have screened and confirmed a set of genes that are useful for predicting whether a cancer patient, for example a breast cancer patient, is likely to respond favorably to chemotherapy. For such prediction, the following six aspects of categorized selection were used: (1) estrogen-related genes, (2) invasion-related genes, (3) immune-related genes, (4) proliferation-related genes, (5) cell cycle-related genes, and (6) other genes. More specifically, the genes selected by the present inventors include ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2), CTSL2 (Cathepsin V), MMP11 (Matrix Metallopeptidase 11), TFRC (Transferrin Receptor), CX3CR1 (C-X3-C Motif Chemokine Receptor 1), KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), KPNA2 (Karyopherin Subunit Alpha 2), AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), KIF23 (Kinesin Family Member 23), JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1).
[0185] Algorithms for predicting breast cancer prognosis and the efficacy of anticancer chemotherapy
[0186] The decision index (DI) was calculated using the regression coefficient (weight) and correction coefficient of the 21 genes obtained from the prediction model. The prediction model was constructed using the Lasso regression method during the algorithm building process to estimate the decision index value for 250 patients, and was validated on 93 patients and then clinically validated on 413 patients.
[0187] The 21 genes are: (1) the first group of estrogen-related genes, consisting of ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2); (2) the second group of invasion-related genes, consisting of CTSL2 (Cathepsin V) and MMP11 (Matrix Metallopeptidase 11); (3) the third group of immunity-related genes, consisting of TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1); (4) the third group of immunity-related genes, consisting of KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding And Spindle Associated 1), and SLC7A5 (Solute Carrier Family 7 Member (5) the fourth group of proliferation-related genes, consisting of KPNA2 (Karyopherin Subunit Alpha 2), (5) the fifth group of cell cycle-related genes, consisting of AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23), and (6) the sixth group of other genes, consisting of JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1).
[0188] It was confirmed that the appropriate range of regression coefficient (weight) values for the categories of each of the six gene groups was rational numbers from -2.36 to -0.34 for the first estrogen-related gene group, rational numbers from 0.17 to 0.42 for the second invasion-related gene group, rational numbers from -0.06 to 0.22 for the third immunity-related gene group, rational numbers from 0.01 to 0.73 for the fourth proliferation-related gene group, rational numbers from 0.08 to 0.65 for the fifth cell cycle-related gene group, and rational numbers from -0.58 to -0.02 for the other gene groups, and the appropriate range of correction coefficient values was rational numbers from 35.09 to 47.07.
[0189] The decision index (DI) values were calculated as follows:
[0190] Decision index Index;DI)=0.62×KIF23+0.60×SLC7A5+0.59×KPNA2+0.53×AURKA+0.34×E2F8+0.34×MMP1 1+0.24×SHCBP1+0.20×CTSL2+0.16×CENPE+0.16×TFRC+0.15×KIF18A+0.14×CCNE2+0.04× The DI value calculated using KIF14 + 0.04 × RRM2 + (-0.04) × CX3CR1 + (-0.05) × JMJD5 + (-0.33) × CACNA1D + (-0.36) × ESR1 + (-0.48) × GSTM1 + (-1.45) × PGR + (-2.04) × SCUBE2 + 41.16 and the predictive diagnosis of patient prognosis were analyzed.
[0191] In the present invention, it has been confirmed that breast cancer can be diagnosed for all age groups, in one embodiment, from the 20s to the 80s, and in another embodiment, for the age groups before and after menopause, by using the above-mentioned prognostic score values, and in particular, breast cancer can be diagnosed for early breast cancer patients. It has been confirmed that the composition and method according to the present invention can diagnose breast cancer for ER+ / HER2- breast cancer patients for all age groups, for example, from the 20s to the 80s, or in another embodiment, for the age groups before and after menopause.
[0192] Validation of breast cancer prognosis prediction
[0193] Clinical validation was carried out on 413 ER+ / HER2- breast cancer patients without lymph node metastasis who had been followed up for more than 5 years. The decision index (DI) value was calculated for all patients using the specified prognostic prediction tool. To confirm the relationship between sensitivity and specificity at all cut-off points, a receiver-operating characteristic curve (ROC curve) was drawn, and the area under curve (AUC) for the ROC curve was calculated and compared with existing products. It was confirmed that the results of breast cancer prognosis prediction by the method for providing information on cancer prognosis according to the present invention (FIG. 1A) were more accurate than a commercially available product (Oncotype Dx, FIG. 1B) (see FIG. 1).
[0194] Considering the relationship between the decision index (DI) and the hazard ratio (HR), an optimal cut-off point was set, and a survival analysis was performed for the presence or absence of distant metastasis. As a result, the method for providing information on cancer prognosis according to the present invention was able to confirm excellent predictive power with a hazard ratio of about 6.6 when performed on all patients (see FIG. 2). Using the method for providing information on cancer prognosis according to the present invention, a survival analysis for the presence or absence of distant metastasis was performed for patients aged 50 or under (FIG. 3A) and over 50 (FIG. 3B). According to the present invention, equally excellent performance was confirmed regardless of the age standard of around 50 years old (see FIG. 3).
[0195] Although certain parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents. [Industrial Applicability]
[0196] The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to chemotherapy. According to the present invention, the cancer prognosis can be predicted for all age groups from 20s to 80s, and in particular, the cancer prognosis can be predicted for all women aged 50 or over or under 50.
Claims
1. (a) measuring and normalizing expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in a biological sample obtained from a subject; (b) multiplying the normalized expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in step (a) by regression coefficient (weight) values and calculating a decision index (DI) obtained by summing the weights, The first gene group is ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2); the second group of genes is Cathepsin V (CTSL2) and Matrix Metallopeptidase 11 (MMP11); the third gene group is TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1); the fourth gene group is KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding and Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2); the fifth gene group is AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23); The sixth gene group is JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1); Furthermore, the method for providing information regarding breast cancer prognosis, wherein the decision index (DI) is represented by the following formula 1: [Formula 1] DI=aX(q)+bY(r)+cZ(s)+dK(t)+eL(u)+fM(v) In the above formula 1, q, r, s, t, u, and v each independently represent an integer of 1 or more; a is a rational number between −2.36 and −0.34; The b is a rational number between 0.17 and 0.42; The c is a rational number from −0.06 to 0.22; The d is a rational number between 0.01 and 0.73; The e is a rational number between 0.08 and 0.65; The f is a rational number between −0.58 and −0.02; X(q) is the sum of normalized expression levels of q genes belonging to the first gene group; Y(r) is the sum of normalized expression levels of r genes belonging to the second gene group; Z(s) is the sum of normalized expression levels of s genes belonging to the third gene group; The K(t) is the sum of normalized expression levels of t genes belonging to the fourth gene group; L(u) is the sum of normalized expression levels of u genes belonging to the fifth gene group; M(v) is the sum of normalized expression levels of v genes belonging to the sixth gene group; When q, r, s, t, u, or v is an integer of 2 or more, the multiple q, r, s, t, u, or v values by which the normalized expression levels of each gene belonging to the same gene group are multiplied may be the same or different.
2. The method according to claim 1, wherein the determination index (DI) is obtained by multiplying the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group and the sixth gene group by a regression coefficient (weight) value, adding up the resulting value, and then adding up a correction coefficient to the resulting value.
3. The step of normalizing is ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCN A2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, CRIM1, CYBRD1, DBF4, DDX39, DLGAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERCC6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH, GINS1, GRB7, GTS E1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20A, KIF2C, KIF4A, KIFC1, LMN B1, LMN B2, LRIG1, LRRC48, LRRC59, MAD2L1, MARCH8, MCM10, MCM2, MCM6, MELK, MK I67, MLF1IP, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYT1, PLK1, PLK4, PRC1, PTTG1, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLP0, SETBP1, SF3B3, SHMT2, SLC25A12, SPAG5, SPC25, SQL E, STAR D13, STIL, STMN1, SYNC, TACC3, TK1, TOP2A, TPX2, TRIP13, TROAP, TTK, UBE2C, UBE2S, ZWINT, C10orf76, C12orf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNP K, HNRNP L, HNRNP R, KHDRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, PKNox1, PPHLN1, RR N3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11, WDR33,The method according to claim 1, wherein the expression level of each gene group is normalized using one or more reference genes selected from the group consisting of ZNF143 and ZNF143.
4. a biological sample obtained from a subject includes a preparation for measuring expression levels of a first gene group, a second gene group, a third gene group, a fourth gene group, a fifth gene group, and a sixth gene group; The first gene group is ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2); the second group of genes is Cathepsin V (CTSL2) and Matrix Metallopeptidase 11 (MMP11); the third gene group is TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1); the fourth gene group is KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding and Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2); the fifth gene group is AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23); The sixth gene group is JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1); A formulation for predicting the prognosis of breast cancer, which provides a decision index (DI) represented by the following formula 1: [Formula 1] DI=aX(q)+bY(r)+cZ(s)+dK(t)+eL(u)+fM(v) In the above formula 1, q, r, s, t, u, and v each independently represent an integer of 1 or more; a is a rational number between −2.36 and −0.34; The b is a rational number between 0.17 and 0.42; The c is a rational number from −0.06 to 0.22; The d is a rational number between 0.01 and 0.73; The e is a rational number between 0.08 and 0.65; The f is a rational number between −0.58 and −0.02; X(q) is the sum of normalized expression levels of q genes belonging to the first gene group; Y(r) is the sum of normalized expression levels of r genes belonging to the second gene group; Z(s) is the sum of normalized expression levels of s genes belonging to the third gene group; The K(t) is the sum of normalized expression levels of t genes belonging to the fourth gene group; L(u) is the sum of normalized expression levels of u genes belonging to the fifth gene group; M(v) is the sum of normalized expression levels of v genes belonging to the sixth gene group; When q, r, s, t, u, or v is an integer of 2 or more, the multiple q, r, s, t, u, or v values by which the normalized expression levels of each gene belonging to the same gene group are multiplied may be the same or different.
5. ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCNA2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, CRIM1, CYB RD1, DBF4, DDX39, DLGAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERC C6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH, GINS1, GRB7, GTSE1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20 A, KIF2C, KIF4A, KIFC1, LMNB1, LMNB2, LRIG1, LRRC48, LRRC59, MAD2L1, MAR CH8, MCM10, MCM2, MCM6, MELK, MKI67, MLF1IP, MYBL2, NCAPG, NCAPG2, NCAP H, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYT1, PLK1, PLK4, PRC1 , PTTG1, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLP0, SETBP1, SF3B3, SH MT2, SLC25A12, SPAG5, SPC25, SQLE, STARD13, STIL, STMN1, SYNC, TACC3, TK 1, TOP2A, TPX2, TRIP13, TROAP, TTK, UBE2C, UBE2S, ZWINT, C10orf76, C12o rf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNPK, HNRNPL, HNRNPR, KH DRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, P KNOX1, PPHLN1, RRN3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11, WDR33,The preparation according to claim 4, further comprising a preparation for measuring the expression level of any one or more reference genes selected from the group consisting of:
6. (a) a detection unit that measures and normalizes expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group in a biological sample obtained from a subject; (b) a calculation unit that multiplies each of the expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group normalized by the detection unit by a regression coefficient (weight) value and calculates a decision index (Decision Index) obtained by adding up the multiplication results; (c) an output unit that predicts and outputs a prognosis of the cancer of the subject based on the determination index obtained by the calculation unit; The first gene group is ESR1 (Estrogen Receptor 1), PGR (Progesterone Receptor), and SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2); the second group of genes is Cathepsin V (CTSL2) and Matrix Metallopeptidase 11 (MMP11); the third gene group is TFRC (Transferrin Receptor) and CX3CR1 (C-X3-C Motif Chemokine Receptor 1); the fourth gene group is KIF14 (Kinesin Family Member 14), RRM2 (Ribonucleotide Reductase Regulatory Subunit M2), SHCBP1 (SHC Binding and Spindle Associated 1), SLC7A5 (Solute Carrier Family 7 Member 5), and KPNA2 (Karyopherin Subunit Alpha 2); the fifth gene group is AURKA (Aurora Kinase A), CCNE2 (Cyclin E2), CENPE (Centromere Protein E), E2F8 (E2F transcription factor 8), KIF18A (Kinesin Family Member 18A), and KIF23 (Kinesin Family Member 23); The sixth gene group is JMJD5 (Lysine Demethylase 8), CACNA1D (Calcium Voltage-Gated Channel Subunit Alpha1 D), and GSTM1 (Glutathione S-Transferase Mu 1); Furthermore, the decision index (DI) of the breast cancer prognostic diagnostic device is represented by the following formula 1: [Formula 1] DI=aX(q)+bY(r)+cZ(s)+dK(t)+eL(u)+fM(v) In the above formula 1, q, r, s, t, u, and v each independently represent an integer of 1 or more; a is a rational number between −2.36 and −0.34; The b is a rational number between 0.17 and 0.42; The c is a rational number from −0.06 to 0.22; The d is a rational number between 0.01 and 0.73; The e is a rational number between 0.08 and 0.65; The f is a rational number between −0.58 and −0.02; X(q) is the sum of normalized expression levels of q genes belonging to the first gene group; Y(r) is the sum of normalized expression levels of r genes belonging to the second gene group; Z(s) is the sum of normalized expression levels of s genes belonging to the third gene group; The K(t) is the sum of normalized expression levels of t genes belonging to the fourth gene group; L(u) is the sum of normalized expression levels of u genes belonging to the fifth gene group; M(v) is the sum of normalized expression levels of v genes belonging to the sixth gene group; When q, r, s, t, u, or v is an integer of 2 or more, the multiple q, r, s, t, u, or v values by which the normalized expression levels of each gene belonging to the same gene group are multiplied may be the same or different.
7. The diagnostic device of claim 6, wherein the determination index (DI) is obtained by multiplying the expression levels of each of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group normalized by the detection unit by a regression coefficient (weight) value, and adding up the resulting value and additionally adding a correction coefficient to the resulting value.
8. the detection unit normalizes expression levels of the first gene group, the second gene group, the third gene group, the fourth gene group, the fifth gene group, and the sixth gene group to an expression level of a reference gene; The reference genes are ACTB, APOBEC3B, ASF1B, ASPM, AURKB, BAG1, BCL2, BIRC5, BLM, BUB1, BUB1B, C14orf45, C16orf61, C7orf63, CCNNA2, CCNB1, CCNB2, CCNE1, CCT5, CD68, CDC20, CDC25A, CDC45, CDC6, CDCA3, CDCA8, CDK1, CDKN3, CENPA, CENPF, CENPM, CENPN, CEP55, CHEK1, CIRBP, CKS2, CRIM1, CYBRD1, DBF4, DDX39, DLGAAP5, DNMT3B, DONSON, DTL, E2F1, ECHDC2, ERBB2, ERCC6L, ESPL1, EXO1, EZH2, FAM64A, FANCI, FBXO5, FEN1, FOXM1, GAPDH, GINS1, GRB7, GTSSE1, GUSB, HJURP, HMMR, HN1, IFT46, KIF11, KIF15, KIF18B, KIF20A, KIF2C, KIF4A, KIFC1, LMNBI, LMNBI, LRIG1, LRRC48, LRRC59, MAD2L1, MARCH8, MCM10, MCM2, MCM6, MELK, MK167, MLFIIP, MYBL2, NCAPG, NCAPG2, NCAPH, NDC80, NEK2, NUP93, NUSAP1, OIP5, PBK, PDSS1, PKMYTI, PLKI, PLK4, PRCI, PTTGI, RACGAP1, RAD51, RAD51AP1, RAI2, RFC4, RPLPO, SETBP1, SF3B3, SHMT2, SLC25A12, SPAG5, SPC25, SQLE, STARDI3, STIL, STMN1, SYNC, TACC3, TK1, TOP2A, TPX2, TRIP13, TROAP, TIK, UBE2C, UBE2S, ZWINT, C10orf76, C12orf72, CIAO1, CNOT4, DBR1, DND1, FBXO42, GRK4, HNRNPk, HNRNPL, HNRNPR, KHDRBS1, KLRAQ1, LACE1, LOC148189, LOC285033, LOC493754, MRPL44, NRF1, PKNox1, PPHLN1, RRNS3P3, SENP8, SLC4A1AP, TARDBP, THRAP3, TTLL11, WDR33,The diagnostic device according to claim 6, wherein the diagnostic agent is any one or more selected from the group consisting of ZNF143 and ZNF143.
Citation Information
Patent Citations
Breast cancer prognosis prediction tool using next-generation sequencing of breast cancer prognostic genes
KR1020180052985A
System for predicting post-surgery prognosis or anticancer drug compatibility of advanced gastric cancer patients
WO2018169145A1
